RecruitingPHASE1, PHASE2NCT04676048

ASC618 Gene Therapy in Hemophilia A Patients

Studying Moderate hemophilia A

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: ASC Therapeutics
Intervention: ASC618(biological)
Enrollment: 12 enrolled
Eligibility: 18 years · MALE
Timeline: 2022 – 2026

Study locations (1)

Arkansas Children's Hospital, Little Rock, Arkansas, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04676048 on ClinicalTrials.gov

Other trials for Moderate hemophilia A

Additional recruiting or active studies for the same condition.

RECRUITINGNCT05022459
Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis
Wayne State University
ACTIVE NOT RECRUITINGPHASE4NCT05181618
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
Hoffmann-La Roche

See all trials for Moderate hemophilia A →

← Back to all trials